Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
Rhea-AI Summary
Royalty Pharma (Nasdaq:RPRX) agreed to acquire a portion of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 ATTR-CM antibody cliramitug for up to $425 million, including $125 million upfront. Royalty Pharma will receive a 3%–4% royalty on worldwide net sales of cliramitug.
Royalty Pharma plans to pay Neurimmune an additional $125 million in the first quarter of 2027, with a further $175 million contingent on clinical and regulatory milestones. Cliramitug is in the Phase 3 DepleTTR-CM trial, with results expected in 2028 based on AstraZeneca guidance, targeting the >$7 billion ATTR-CM market, which grew over 40% in 2025.
Positive
- Up to $425 million deployed to secure 3%–4% cliramitug royalty
- $125 million additional payment scheduled for Q1 2027
- Exposure to ATTR-CM market that exceeded $7 billion sales in 2025
Negative
- Total consideration of up to $425 million tied to a Phase 3 asset
- $175 million of payments depend on clinical and regulatory milestones
News Explained
Royalty Pharma reports that it has acquired the cliramitug royalty interest, moving the transaction beyond an agreement announcement; in exchange for up to
News Market Reaction – RPRX
In the Jul 22 session, RPRX gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | Royalty acquisition | Positive | -0.2% | Acquired remaining Evrysdi royalty interest with upfront and milestone payments |
| Dec 16 | Royalty acquisition | Positive | -0.4% | Acquired royalty interests in Nuvalent oncology candidates for up to consideration |
| Nov 04 | Royalty acquisition | Positive | +1.4% | Acquired a royalty interest in AMVUTTRA from Blackstone Life Sciences |
| Aug 25 | Royalty acquisition | Positive | -0.9% | Announced acquisition of Imdelltra royalty interest with milestone option |
| May 16 | Manager acquisition | Positive | +0.7% | Completed acquisition of external manager following shareholder approval |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Acquisition-tagged news produced mixed reactions: 3 of 5 were negative, 2 were positive, and the average move was 0.12%.
Key Terms
ttr-fibril-depleting antibody medical
ttr amyloidosis medical
royalty interest financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to
Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently in the Phase 3 DepleTTR-CM trial with results expected in 2028i.
“We are excited to acquire a royalty interest in cliramitug,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Cliramitug combines a differentiated scientific approach with promising clinical data and addresses a rapidly growing market with significant unmet need. Cliramitug is our second recent investment in this indication and has the potential to transform the ATTR-CM disease course. This therapy further bolsters our development-stage pipeline, and we believe it will become a valuable contributor to our portfolio over the long term.”
“We are developing a novel class of therapeutics and are excited to enter into a partnership with Royalty Pharma related to our cardiac ATTR depleter, cliramitug,” said Roger M. Nitsch, President and Chief Executive Officer of Neurimmune. “Today’s transaction is providing funds to further advance our internal R&D pipeline while retaining the majority of our royalty and milestone interests in cliramitug.”
The ATTR-CM market grew over
Transaction terms
Under the terms of the agreement, Royalty Pharma will provide Neurimmune up to
Advisors
Goodwin Procter and Maiwald acted as legal advisors to Royalty Pharma.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
_______________________________________
i Phase 3 results timing based on AstraZeneca guidance.
